Drugs / ASN51
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT06232109 | Feb → Jul 2024 | — | Asceneuron S.A. | Completed | No outcome recorded |
| Phase 1 | NCT05725005 | Jan → Apr 2023 | — | Asceneuron S.A. | Completed | No outcome recorded |
| Phase 1 | NCT06390098 | Aug → Oct 2021 | — | Asceneuron S.A. | Completed | No outcome recorded |
| Phase 1 | NCT04759365 | Jun 2021 → Aug 2022 | Alzheimer disease | Asceneuron Pty Ltd. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 21 trial | ||||||
| Phase 2 | NCT06677203 | Oct → Nov 2024 | Alzheimer disease | Asceneuron S.A. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASN51 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06390098 ↗ |
| Route | Oral | “ASN51 will be administered as an oral capsule” NCT04759365 ↗ |